In pooled analyses with TCLs/TCLs + IFNγ and FTDs (n = 186, Figure 1A), the mean proportion of tumor-reactive CD8+ TILs of melanoma samples, regardless of previous anti-PD-1 therapy, far surpassed other cohorts (p < 0.001). This evidence concerns the gene CD8A and neoplasm.